Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is ACTH? Benefits, Research & Safety
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Also known as:
Adrenocorticotropic Hormone
Corticotropin
Adrenocorticotropin
UK summary: UK prescription-only medicine. Synacthen (synthetic ACTH analogue) is used by NHS endocrinology for adrenal-function testing. Prohibited at all times under WADA S2.
Quick Facts
Category
Hormonal & Endocrine
Half-Life
Approximately 10-20 minutes in plasma
UK Status
ACTH/cosyntropin (Synacthen) approved for diagnostic use and some therapeutic indications.
EU Status
Similar approvals for diagnostic and therapeutic uses.
Overview
Adrenocorticotropic hormone (ACTH) is a 39-amino acid peptide hormone produced by the anterior pituitary gland as part of the hypothalamic-pituitary-adrenal (HPA) axis. It is the primary regulator of cortisol production by the adrenal glands.
ACTH is derived from a larger precursor protein called proopiomelanocortin (POMC), which also gives rise to other important peptides including α-MSH (melanocyte-stimulating hormone) and β-endorphin. This shared origin explains some of ACTH's effects beyond cortisol regulation.
Physiologically, ACTH responds to stress signals from the hypothalamus (via corticotropin-releasing hormone, CRH) to stimulate cortisol release. This is essential for the body's stress response, metabolism, immune function, and maintaining homeostasis.
Synthetic ACTH and its analogues (particularly cosyntropin/tetracosactide) have important medical applications. Diagnostically, ACTH stimulation tests are used to assess adrenal function. Therapeutically, ACTH is approved for treating infantile spasms (West syndrome) and has been used for various inflammatory conditions.
ACTH's immunomodulatory and anti-inflammatory effects, partly independent of cortisol, have led to interest in conditions like multiple sclerosis, rheumatoid arthritis, and inflammatory disorders.
Evidence standards summary
ACTH — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
AStrong human evidenceOverall grade against our evidence grading methodology.
UK prescription-only medicine. Synacthen (synthetic ACTH analogue) is used by NHS endocrinology for adrenal-function testing. Prohibited at all times under WADA S2.
02Human evidence grade
AStrong human evidenceStrength of evidence from published human trials.
03Preclinical evidence grade
AStrong human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: ACTH/cosyntropin (Synacthen) approved for diagnostic use and some therapeutic indications.
- EU: Similar approvals for diagnostic and therapeutic uses.
- Notes: Cosyntropin/tetracosactide (ACTH 1-24) is widely available for diagnostic testing. Repository corticotropin (Acthar Gel) is approved in the US for various conditions including infantile spasms, MS exacerbations, and rheumatic disorders. Availability and indications vary by jurisdiction.
05Approved medical uses
- Synacthen test for adrenal-function evaluation (synthetic ACTH analogue — NHS hospital use).
06Unapproved / promotional claims
- Boost cortisol for energy / performance / training.
- Athletic performance enhancement.
07Common internet claims
- Marketed by some bodybuilding sources as a cortisol boost.
- Sold by research-peptide retailers as ACTH 1-39 or fragments.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “ACTH boosts cortisol for energy / performance” | E | No | High | Pharmacological cortisol elevation is not a wellness strategy; documented harms with chronic exposure. ACTH is a UK POM used in defined clinical contexts. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Pharmacological cortisol elevation: weight gain, mood disturbance, immunosuppression, osteoporosis, hyperglycaemia with chronic exposure.
- Adrenal suppression after prolonged use.
- WADA S2 prohibited.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Prohibited in sportWADA strict-liability framing applies.
13UK legal position
UK: Prescription-only (UK POM)
ACTH/cosyntropin (Synacthen) approved for diagnostic use and some therapeutic indications.
14EU legal position
Similar approvals for diagnostic and therapeutic uses.
15What this page cannot tell you
- Whether a grey-market 'ACTH' product contains the labelled compound.
- Long-term consequences of self-administered cortisol elevation.
16Last reviewed
17Citation quality score
AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- No legitimate research basis for healthy-adult ACTH self-administration.
19Safer alternatives / established care pathways
- NHS endocrinology referral if adrenal-function concerns are clinical.
- Exercise, sleep, and stress management for energy concerns.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the clinical reason ACTH might be relevant for me (vs a routine cortisol test)?
Discovery & History
ACTH was among the first pituitary hormones to be characterised. In 1943, researchers established that the pituitary released a factor stimulating the adrenal cortex, naming it adrenocorticotropic hormone.
The isolation and purification of ACTH was achieved by various researchers in the late 1940s and early 1950s. Li and Evans, as well as Sayers and colleagues, made key contributions to understanding its structure and function.
By 1960, the complete amino acid sequence of ACTH had been determined, and shortly after, the hormone was synthesised. Researchers discovered that only the first 24 amino acids (ACTH 1-24) were necessary for full biological activity, leading to development of cosyntropin/tetracosactide.
The discovery that ACTH derived from proopiomelanocortin (POMC) alongside melanocortin peptides and β-endorphin explained some of its diverse biological effects and led to greater understanding of neuroendocrine regulation.
ACTH has been used therapeutically since the 1950s, initially for inflammatory conditions. Its use in infantile spasms was recognised in the 1950s and remains an approved indication today. Repository corticotropin (Acthar Gel) continues to be used for various conditions.
Mechanism of Action
ACTH exerts its primary effects through melanocortin 2 receptor (MC2R) on adrenal cortex cells:
**MC2R Activation in Adrenal Cortex**
ACTH binding to MC2R requires the accessory protein MRAP:
- Activates adenylate cyclase and increases cAMP
- Stimulates steroidogenic enzymes
- Promotes cortisol synthesis and release
- Also stimulates adrenal androgen production
**Cortisol-Mediated Effects**
The primary consequence of ACTH release is cortisol production:
- Anti-inflammatory and immunomodulatory effects
- Metabolic regulation (glucose, protein, fat)
- Stress response adaptation
- Feedback inhibition of ACTH release
**Direct Immunomodulatory Effects**
ACTH has effects beyond cortisol stimulation:
- Immune cells express melanocortin receptors
- Direct anti-inflammatory effects independent of cortisol
- Modulation of cytokine production
- These may explain efficacy in some conditions
**Melanocortin Effects**
ACTH has activity at other melanocortin receptors:
- Some MC1R, MC3R, MC4R, MC5R activity
- Contributes to skin pigmentation effects
- Potential metabolic effects
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for infantile spasms/West syndrome (approved)
- 2Diagnostic use in adrenal function testing
- 3Treatment of multiple sclerosis exacerbations
- 4Management of nephrotic syndrome
- 5Anti-inflammatory effects in various conditions
- 6Treatment of rheumatic and inflammatory disorders
Claim vs Evidence
How popular claims about ACTH stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “ACTH boosts cortisol for energy / performance” | E | No | High | Pharmacological cortisol elevation is not a wellness strategy; documented harms with chronic exposure. ACTH is a UK POM used in defined clinical contexts. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Variable by indication; typically 25-250 μg for stimulation tests; higher doses for therapeutic use |
| Frequency | Indication-dependent |
| Duration | Short-term for stimulation tests; variable for therapeutic use |
| Notes | ACTH products (cosyntropin, repository corticotropin) are prescription medications with defined dosing for specific indications. Treatment should be under specialist supervision with appropriate monitoring. |
Administration Routes
Routes studied in research settings (educational only):
- Intramuscular injection (most common)
- Intravenous (diagnostic tests)
- Subcutaneous (some protocols)
| Half-Life | Stability |
|---|---|
| Approximately 10-20 minutes in plasma | Commercial preparations have defined stability; requires appropriate storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Fluid retention
- Increased appetite and weight gain
- Mood changes, irritability
- Elevated blood glucose
- Skin changes (acne, increased pigmentation)
- Hypertension
Rare Risks & Concerns
- Adrenal suppression with prolonged use
- Serious infections (immunosuppression)
- Osteoporosis with chronic use
- Psychiatric disturbances
- Cushing syndrome features
Contraindications
- Systemic fungal infections
- Primary adrenal insufficiency
- Scleroderma
- Osteoporosis
- Peptic ulcer disease
- Recent surgery or live vaccination
UK & EU Regulatory Context
🇬🇧 United Kingdom
ACTH/cosyntropin (Synacthen) approved for diagnostic use and some therapeutic indications.
🇪🇺 European Union
Similar approvals for diagnostic and therapeutic uses.
Cosyntropin/tetracosactide (ACTH 1-24) is widely available for diagnostic testing. Repository corticotropin (Acthar Gel) is approved in the US for various conditions including infantile spasms, MS exacerbations, and rheumatic disorders. Availability and indications vary by jurisdiction.
Clinical Studies Summary
ACTH for Infantile Spasms
Clinical trials confirming ACTH as first-line treatment for infantile spasms (West syndrome).
Paediatric neurology journalsView on PubMed
Repository Corticotropin in Nephrotic Syndrome
Studies evaluating ACTH for proteinuric kidney diseases.
Nephrology journalsView on PubMed
Looking for ACTH?
Source research-grade ACTH from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about ACTH
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the clinical reason ACTH might be relevant for me (vs a routine cortisol test)?
UK regulatory & safety context
Related Peptides
Alpha-MSH
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
Learn moreBeta-Endorphin
The body's natural opioid peptide involved in pain modulation, stress response, and reward, mediating the 'runner's high' and other euphoric states.
Learn more